JP2013505968A - フィラデルフィア染色体陽性白血病の治療方法 - Google Patents

フィラデルフィア染色体陽性白血病の治療方法 Download PDF

Info

Publication number
JP2013505968A
JP2013505968A JP2012531186A JP2012531186A JP2013505968A JP 2013505968 A JP2013505968 A JP 2013505968A JP 2012531186 A JP2012531186 A JP 2012531186A JP 2012531186 A JP2012531186 A JP 2012531186A JP 2013505968 A JP2013505968 A JP 2013505968A
Authority
JP
Japan
Prior art keywords
leukemia
csf
agent
composition
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012531186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505968A5 (cg-RX-API-DMAC7.html
Inventor
デヴェンドラ ケシャオラオ ヒワセ
ティモシー ピーター ヒューズ
アンヘル フランシスコ ロペス
ギーノ ルイージ ヴァイロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2013505968A publication Critical patent/JP2013505968A/ja
Publication of JP2013505968A5 publication Critical patent/JP2013505968A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012531186A 2009-10-01 2010-10-01 フィラデルフィア染色体陽性白血病の治療方法 Pending JP2013505968A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24766909P 2009-10-01 2009-10-01
US61/247,669 2009-10-01
PCT/AU2010/001295 WO2011038467A1 (en) 2009-10-01 2010-10-01 Method of treatment of philadelphia chromosome positive leukaemia

Publications (2)

Publication Number Publication Date
JP2013505968A true JP2013505968A (ja) 2013-02-21
JP2013505968A5 JP2013505968A5 (cg-RX-API-DMAC7.html) 2013-07-18

Family

ID=43825444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012531186A Pending JP2013505968A (ja) 2009-10-01 2010-10-01 フィラデルフィア染色体陽性白血病の治療方法

Country Status (8)

Country Link
US (7) US20120244116A1 (cg-RX-API-DMAC7.html)
EP (1) EP2470212A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013505968A (cg-RX-API-DMAC7.html)
CN (1) CN102665756A (cg-RX-API-DMAC7.html)
AU (1) AU2010302961A1 (cg-RX-API-DMAC7.html)
CA (1) CA2775155A1 (cg-RX-API-DMAC7.html)
IL (1) IL218774A0 (cg-RX-API-DMAC7.html)
WO (1) WO2011038467A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017122736A1 (ja) * 2016-01-13 2017-07-20 学校法人早稲田大学 白血病幹細胞のニッチ形成抑制活性を有する海洋生物由来の抽出物、化合物及び医薬組成物
US10314834B2 (en) 2015-09-10 2019-06-11 University Of Yamanashi Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
ES2550639T3 (es) 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
EA027770B1 (ru) * 2011-11-06 2017-08-31 БЕТА КЭТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ПРИМЕНЕНИЕ ИНГИБИТОРА Wnt/β-КАТЕНИНОВОГО МЕХАНИЗМА ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЯ И РАССТРОЙСТВА, СВЯЗАННОГО С АКТИВНОСТЬЮ ТРАНСДУЦИН β-ПОДОБНОГО БЕЛКА 1 (TBL1), ПРЕДСТАВЛЯЮЩЕГО СОБОЙ МИЕЛОПРОЛИФЕРАТИВНУЮ НЕОПЛАЗИЮ ИЛИ ХРОНИЧЕСКИЙ МИЕЛОИДНЫЙ ЛЕЙКОЗ
JP2014533262A (ja) * 2011-11-11 2014-12-11 ファイザー・インク 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド
US9801851B2 (en) * 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
US9220706B2 (en) 2012-06-01 2015-12-29 National Institutes Of Health (Nih) Inhibition of leukemic stem cells by PP2A activating agents
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
CN108473487B (zh) 2016-12-13 2021-08-03 普林斯顿药物研发公司 一种蛋白激酶抑制剂
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN120919138A (zh) * 2025-08-19 2025-11-11 深圳大学 一种用于治疗白血病的药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509835A (ja) * 2000-03-06 2004-04-02 ユニヴァーシティ　オブ　ケンタッキー　リサーチ　ファンデーション 血液癌前駆細胞を障害する方法およびその関連化合物
JP2008536853A (ja) * 2005-04-13 2008-09-11 ブリストル−マイヤーズ スクイブ カンパニー 癌治療のための、組み合わせ、方法および組成物
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070013A (en) * 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
DK0486572T3 (da) * 1989-08-11 1998-05-04 Amrad Corp Ltd Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
US5281699A (en) * 1990-06-01 1994-01-25 Tanox Biosystems, Inc. Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
US5112961A (en) * 1990-07-18 1992-05-12 Schering Corporation Dna encoding subunits of a high affinity gm-csf receptor
EP2091967A4 (en) * 2006-11-03 2010-05-05 St Vincents Inst Med Res CRYSTALLINE COMPOSITION OF GM-CSF / GM-CSFR
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
ES2550639T3 (es) * 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509835A (ja) * 2000-03-06 2004-04-02 ユニヴァーシティ　オブ　ケンタッキー　リサーチ　ファンデーション 血液癌前駆細胞を障害する方法およびその関連化合物
JP2008536853A (ja) * 2005-04-13 2008-09-11 ブリストル−マイヤーズ スクイブ カンパニー 癌治療のための、組み合わせ、方法および組成物
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014025367; Ａ．　Ｌ．　Ｌｙｏｎｓ　ｅｔ　ａｌ．: Ｂｌｏｏｄ（ＡＳＨ　Ａｎｎｕａｌ　Ｍｅｅｔｉｎｇ　Ａｂｓｔｒａｃｔｓ） ｖｏｌ．１０６, 2005 *
JPN6014025369; Ｃ．　Ｈ．　Ｊａｍｉｅｓｏｎ: ＡＳＨ　Ｅｄｕｃａｔｉｏｎ　Ｐｒｏｇｒａｍ　Ｂｏｏｋ ｖｏｌ．２００８，　Ｎｏ．１, 2008, ｐ．４３６-４４２ *
JPN6014025372; Ｙ．　Ｃｈｅｎ　ｅｔ　ａｌ．: Ｎａｔｕｒｅ　Ｇｅｎｅｔｉｃｓ ｖｏｌ．４１，　Ｎｏ．７, 200907, ｐ．７８３-７９３ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10314834B2 (en) 2015-09-10 2019-06-11 University Of Yamanashi Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation
WO2017122736A1 (ja) * 2016-01-13 2017-07-20 学校法人早稲田大学 白血病幹細胞のニッチ形成抑制活性を有する海洋生物由来の抽出物、化合物及び医薬組成物
JPWO2017122736A1 (ja) * 2016-01-13 2018-11-22 学校法人早稲田大学 白血病幹細胞のニッチ形成抑制活性を有する海洋生物由来の抽出物、化合物及び医薬組成物
US10933044B2 (en) 2016-01-13 2021-03-02 Waseda University Marine organism-derived extract, compound, and medical composition having niche formation suppressing activity of leukemic stem cells

Also Published As

Publication number Publication date
AU2010302961A1 (en) 2012-04-19
CN102665756A (zh) 2012-09-12
CA2775155A1 (en) 2011-04-07
IL218774A0 (en) 2012-06-28
US20210292424A1 (en) 2021-09-23
US20250122295A1 (en) 2025-04-17
EP2470212A4 (en) 2013-12-04
US20160304616A1 (en) 2016-10-20
US20200277389A1 (en) 2020-09-03
WO2011038467A1 (en) 2011-04-07
US20150093355A1 (en) 2015-04-02
US20120244116A1 (en) 2012-09-27
US20170362328A1 (en) 2017-12-21
EP2470212A1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
US20250122295A1 (en) Method of treatment of philadelphia chromosome positive leukemia
KR102799514B1 (ko) 급성 골수성 백혈병(acute myeloid leukaemia) 치료를 위한 항 cd70-항체 argx-110의 용도
JP6611709B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
EP2119452B1 (en) Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
US10487152B2 (en) IgE antibodies for the inhibition of tumor metastasis
JP2014534250A (ja) 抗ｃｄ２０抗体とヒトｉｌ−１５を用いる併用療法
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
KR20210031679A (ko) 수모-활성화 효소 저해제 및 항-cd20 항체의 투여
JP2024001191A (ja) 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法
JP2020528061A (ja) ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
WO2020183147A1 (en) Immunotherapy combined with an anti-cd38 antibody
JP7196311B2 (ja) 抗ｔｉｍ－３抗体とその利用
US20240368288A1 (en) Bispecific anti-flt3/cd3 antibodies and methods of use
US20220389104A1 (en) Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
US20220340687A1 (en) Methods of treatment using omalizumab
IL294113A (en) ccr5-binding factor for the treatment of ccr5-positive metastatic cancer
EP4320153A1 (en) Methods for the treatment of anaplastic large cell lymphoma

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140918

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150323